NeoPharm reiterated at buy by JMP

NeoPharm, Inc. was reiterated at strong buy with a $19 price target by JMP Securities analyst Charles C. Duncan after the company presented phase 3 trial results at the AANS meeting. Median survival data of NeoPharm's cintredekin besudotox exceeds expectations, lowering risk in the trial. Phase ½ studies of cintredekin besudotox (CBtox) in recurrent glioblastoma showed median survival of more than one year, surpassing the analyst's expectations. Shares of the Lake Forest, Ill., biopharmaceutical company were up 15 cents, or 1.97%, at $7.75 on volume of 318,838 shares versus the three-month running average of 289,646 shares. (Nasdaq: NEOL)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.